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IVIG regulates the survival of 
human but not mouse neutrophils
Christoph Schneider1, Simone Wicki1, Stefanie Graeter1, Tankica M. Timcheva1, Christian 
W. Keller2, Isaak Quast  2,3, Danila Leontyev4, Iglika K. Djoumerska-Alexieva5, Fabian 
Käsermann6, Stephan M. Jakob7, Petya A. Dimitrova5, Donald R. Branch4, Richard D. 
Cummings8, Jan D. Lünemann2, Thomas Kaufmann  1, Hans-Uwe Simon1 & Stephan von 
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Intravenous immunoglobulin (IVIG) are purified IgG preparations made from the pooled plasma from 
thousands of healthy donors and are being tested in preclinical mouse models. Inherent challenges, 
however, are the pluripotency of IVIG and its xenogeneicity in animals. IVIG can alter the viability of 
human neutrophils via agonistic antibodies to Fas and Siglec-9. In this study, we compared the effects 
of IVIG on human and mouse neutrophils using different death assays. Different commercial IVIG 
preparations similarly induced cytokine-dependent death in human neutrophils, whereas they had no 
effects on the survival of either peripheral blood or bone marrow neutrophils from C57BL/6 or BALB/c 
mice. F(ab’)2 but not Fc fragments of IVIG induced death of human neutrophils, whereas neither of these 
IVIG fragments, nor agonistic monoclonal antibodies to human Fas or Siglec-9 affected the viability of 
mouse neutrophils. Pooled mouse IgG, which exhibited a different immunoprofile compared to IVIG, 
also had no effect on mouse cells. Together, these observations demonstrate that effects of IVIG on 
neutrophil survival are not adequately reflected in current mouse models, despite the key role of these 
cells in human inflammatory and autoimmune diseases.
Intravenous immunoglobulin (IVIG) preparations consist primarily of IgG antibodies produced from pooled 
plasma from thousands of healthy donors. Initially used for the antibody replacement therapy of humoral 
immunodeficiencies, to date their value as anti-inflammatory drugs is appreciated for the treatment of a stead-
ily increasing number of disorders across medical disciplines, including rheumatology, neurology, dermatology, 
gynecology, and transplantation medicine1–4. Given their polyclonal nature, these immunoglobulin preparations 
contain a wide range of specificities for antigens5, reflecting the combined antibody repertoire of the donor popu-
lation6. Within this repertoire functional antibodies with immunomodulatory capacity have been identified that 
target virtually all arms of the humoral and cellular immune systems, and include immunoregulatory, neutraliz-
ing, or anti-idiotypic antibodies1, 6–9.
Animal models revealed immunomodulatory antibodies in IVIG that ameliorate the course of autoimmune 
disorders, such as lupus, myasthenia gravis, pemphigus vulgaris and antiphospholipid syndrome (APS) by target-
ing specific pathogenetic mechanisms10. Based on these in vivo experiments, it was proposed that specific IVIG 
(sIVIG) enriched for the active compounds may have an advantage over regular IVIG10. Other studies suggest that 
sialylation of both the Fc and Fab regions of IgG may contribute to the anti-inflammatory effects of IVIG11–13; yet, 
conflicting evidence in models of immune thrombocytopenia (ITP) and rheumatoid arthritis (RA) indicates the 
need for further investigations3, 14–16, in which potential experimental limitations related to the disease model or 
to intrinsic characteristics of IVIG are given special attention in terms of study design and data interpretation17, 18. 
The pharmacological complexity of IVIG is determined by its pluripotency6, 17, 19, polyclonality, and origin from 
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different individuals. Notably, these complex human preparations might have xenogeneic effects at least on 
certain immunological players in animals, eventually leading to loss-of-function or gain-of-function effects7. 
Species-related differences in IVIG functions might be common20. It is, therefore, imperative for the design and 
interpretation of future in vivo studies on IVIG to dissect species-related similarities and differences of potential 
IVIG targets.
Neutrophils are key players of innate immunity and often the most predominant leukocyte at the site of 
inflammation, in particular at acute stages of autoimmune or other inflammatory disorders21–23. Upon activa-
tion, these cells cannot only cause substantial tissue damage, but recent evidence suggests that neutrophils play 
an active role in the coordination of innate and adaptive immunity24, 25. In humans, but not in mice, neutrophils 
represent the most frequent leukocytes in the circulation. Neutrophils are short-lived cells and the regulation 
of neutrophil survival is considered as a mechanism to control this innate effector cell26–28. Clinically relevant 
concentrations of IVIG can regulate the survival of neutrophils in a cytokine-dependent manner29, 30. Functional 
antibodies to the death receptor Fas (also called CD95) and to Siglecs have been implicated in the regulation of 
granulocytes by IVIG9, 29–32. In mouse neutrophils, IVIG was reported to limit inhibition of neutrophil apopto-
sis induced by lipopolysaccharide (LPS) stimulation, potentially by blocking LPS-mediated effects, although no 
direct pro-apoptotic activity of IVIG could be demonstrated33.
Here we report our discovery that different commercial IVIG preparations equally induce cytokine-dependent 
death of human neutrophils, whereas mouse neutrophils, regardless of cytokine priming or origin from bone 
marrow or circulation, were resistant to IVIG-induced death. Unexpectedly, we observed no signs of cell death 
in mouse neutrophils following IVIG treatment, neither in terms of genomic DNA fragmentation, phosphatidyl-
serine (PS) redistribution, cell permeability, loss of mitochondrial membrane potential, nor morphology. Human 
neutrophil death was triggered in a F(ab’)2 but not Fc-dependent manner, supporting the notion that specific 
antibodies in IVIG are responsible for granulocyte death in humans. Mouse neutrophils were also resistant to 
homologous pooled IgG from mice, indicating that the use of species-matched pooled IgG may not provide an 
adequate alternative to mimic IVIG effects in animal models. These findings suggest that despite the key role of 
neutrophils in autoimmune disease and other inflammatory disorders, currently used mouse models may not 
reflect important effects of IVIG on human neutrophils.
Results
Different effects of IVIG on human versus mouse neutrophil survival. IVIG can regulate the sur-
vival of human neutrophils, an effect that is enhanced in cells under inflammatory conditions29–31. We compared 
the efficacy of different lots or batches of commercial IVIG preparations to modulate the survival of human and 
mouse neutrophils. Hizentra, Immunovenin-intact, Sandoglobulin, and two lots of Privigen, all at 20 mg/ml, 
a concentration that following high-dose IVIG treatment is typically reached in the circulation34, induced cell 
death in human peripheral blood neutrophils to a similar extent, and this effect was further enhanced following 
priming of cells with human GM-CSF (Fig. 1A). In contrast, none of the preparations had an effect on the survival 
of peripheral blood neutrophils of mice, either in the presence or absence of mouse GM-CSF. In line with pre-
viously published results29, 31, the effects of IVIG on human neutrophil survival were concentration-dependent, 
whereas we observed no death-induction on mouse neutrophils even at high concentrations (Fig. 1B). We also 
investigated the responses of mouse cells from different compartments, but found no death responses to IVIG 
in either peripheral circulatory or in the less mature bone marrow-derived mouse neutrophils from both C57/
BL6 and BALB/c mouse strains, respectively (Fig. 1C, Supplementary Fig. 1). Further, when C57/BL6 mice were 
immunized with complete Freund’s adjuvant (CFA), which is known to induce strong neutrophil responses35, 36. 
The activation marker CD11b was upregulated on neutrophils isolated from spleen (Supplementary Fig. 2), but 
no IVIG-induced neutrophil cell death was observed in neutrophils isolated from spleen or peripheral blood 
(Fig. 1D). Peritoneal injection of IVIG up to 4 g/kg in healthy BALB/c mice did not affect peripheral blood neu-
trophil counts in vivo nor flow cytometric Annexin V staining (Supplementary Fig. 3), a marker for apoptosis. 
Furthermore, intravenous IVIG administration did not alter the frequency of Annexin V+ blood neutrophils in 
BALB/c mice with LPS-induced sepsis (Supplementary Fig. 3). Interestingly, non-rodent peripheral blood neu-
trophils ex vivo from a porcine sepsis model of fecal peritonitis also showed no death response in 24-h cultures in 
the presence of IVIG (Supplementary Fig. 4).
Occurrence of IVIG-induced features of cell death in human but not mouse neutrophils. To fur-
ther investigate the susceptibility of mouse neutrophils toward IVIG-induced death effects, we analyzed various 
markers of cell death. As expected for a sign of spontaneous apoptosis, phosphatidylserine (PS) redistribution to 
the surface was evident in aged human and mouse neutrophil cultures (15 hours) by flow cytometric Annexin V 
staining, which was delayed in the presence of species-matched GM-CSF (Fig. 2A, Supplementary Figs 5 and 6). 
IVIG treatment increased the frequency of Annexin V+ human neutrophils, and this was further enhanced by 
GM-CSF priming. In contrast, IVIG had no effects on either PS redistribution or on propidium iodide uptake 
of mouse neutrophils compared to cytokine-primed or unprimed controls. Similarly, IVIG treatment led to 
increased DNA fragmentation exclusively in human cells (Fig. 2B, Supplementary Fig. 6). We also could detect 
dissipation of the mitochondrial membrane potential (Δψm) in human neutrophils following IVIG treatment 
for 5 hours as a sign of early mitochondrial apoptosis pathway activation (Fig. 2C), whereas there was no effect of 
IVIG on Δψm in mouse neutrophils upon treatment with IVIG.
Morphological characterization by light microscopy revealed signs of spontaneous apoptosis, as expected, 
in 15-hour cultures of both mouse and human neutrophils. The frequency of cells with an apoptotic phenotype 
(cellular shrinkage, nuclear condensation) was enhanced in IVIG-treated human neutrophils, and extensive cyto-
plasmic vacuolization appeared in treated cells in the presence of GM-CSF (Fig. 2D), an observation that has been 
associated with neutrophil death by IVIG29, Siglec-937, or CD4438, under inflammatory conditions. By contrast, 
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we observed no signs of increased cell death or cytoplasmic vacuole formation in mouse neutrophils treated 
with IVIG. Together, these findings indicate that IVIG triggers apoptotic pathways in human but not in mouse 
neutrophils.
IVIG-mediated death effects on human neutrophils are F(ab’)2- but not Fc-mediated. The impli-
cation of Fc- versus specific Fab-mediated effects of IVIG on the regulation of different leukocytes remains to be 
explored1, 17, 29. Therefore, we investigated the effects of whole IVIG with Fc-, or F(ab’)2 (Gammavenin)-fragments 
of pooled IgG on human and mouse neutrophils. The streptococcal cysteine proteinase Ide-S was used to gen-
erate Fc and F(ab’)2 fragments from IVIG39. In line with previous findings29, 30, IVIG and the preparation of 
F(ab’)2-fragments both induced death of human neutrophils that was enhanced in GM-CSF primed cells 
(Fig. 3A). In contrast, we did not observe any effects of Fc fragments of IVIG on the survival of neutrophils. In 
addition, neither Fc-, nor F(ab’)2 preparations affected mouse neutrophils.
The observed findings contribute to accumulating evidence that IVIG mediates the regulation of neutrophil 
survival by antibodies with specificity to human-specific antigenic determinants. Functional antibodies to Fas and 
Siglec-9 are thought to be responsible for the regulatory effects of IVIG on the survival of human neutrophils29, 30. 
Commercial agonistic antibodies to human Fas or Siglec-9 receptors, like IVIG, induced death in human but 
not mouse neutrophils, whereas mouse neutrophils were highly responsive to crosslinked Fas ligand (FasL), in 
accordance with published reports40 (Fig. 3B). Induction of death in human neutrophils by anti-Siglec-9 mon-
oclonal antibody (mAb) was GM-CSF-dependent, which supports the possibility that the cytokine-dependent 
effects of IVIG might be linked to targeting of Siglec-929.
Figure 1. IVIG induces cell death in human but not in mouse polymorphonuclear neutrophils (PMNs) ex vivo. 
Death of human (PMNH), C57BL/6 (PMNBL/6) or BALB/c (PMNBALB/c) mouse neutrophils in the presence or 
absence of priming with species matched GM-CSF, as assessed by flow cytometric ethidium bromide exclusion 
assay. (A) Different commercial IVIG/SCIG preparations similarly induce death of human peripheral blood 
neutrophils, an effect that is enhanced in GM-CSF primed cells. No death is induced in mouse PB neutrophils. 
(B) Comparison of the concentration-effect curves of IVIG in PB PMNH or PMNBL/6 with or without GM-
CSF priming. (C) In mouse neutrophils from both strains, no IVIG-mediated death is observed, neither in 
cells derived from peripheral blood (PB) nor bone marrow (BM). (D) In in vivo primed neutrophils isolated 
from spleen or peripheral blood (PB) no IVIG-induced cell death was observed. Results of 24-h cultures are 
shown. Bars show mean ± SEM. Data are representative of at least 3 (D), 4 (C), 5 (B), or 6 (A) independent 
experiments. *p < 0.05, **p < 0.01, Student t test. Specific death was calculated in comparison to untreated 
controls as outlined in the Materials and Methods section.
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Pooled IgG from mouse sera does not induce death in autologous neutrophils. IVIG prepara-
tions consist primarily of IgG derived from the sera of thousands of donors and hence reflect the IgG antibody 
repertoire of the donor population. Recently, it was reported that the specific recognition of antigens by IgG 
antibodies varies substantially between sera from different species41. Given that IVIG-induced death in human 
neutrophils depends on F(ab’)2-fragments that are responsible for antigen recognition, we wondered if pooled 
IgG from mouse sera would also have the capacity to trigger death in neutrophils of the same species (mice). 
Mouse neutrophils were treated with commercial IgG derived from pooled mouse sera at 20 mg/ml and cell 
death of 15-hour cultures was assessed by annexin V-FITC/PI staining and subsequent flow cytometric analysis. 
Pooled mouse IgG had no effect, neither on PS redistribution nor PI incorporation of unprimed or GM-CSF 
primed cells (Fig. 4A and B). Glycan array technology, a powerful tool to assess immunoprofiles5, 41 was used to 
screen the reactivity of pooled mouse IgG with IVIG to 609 glycan antigens. While human IVIG bound a broad 
range of glycans on the array, recognition by pooled mouse IgG was restricted to only few blood group antigens 
that are also found in bacteria, including GalNAcα1-3(Fucα1-2)Galβ1-3GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAc 
(Supplementary Fig. 7). These findings indicate that pooled mouse sera exhibit a significantly different immuno-
profile compared to IVIG, and do not contain functional antibodies with the capacity to regulate the survival of 
autologous neutrophils.
Discussion
In humans, neutrophils are the most frequent nucleated cells in the circulation (50–70% neutrophils) and are 
involved in the pathogenesis of a wide range of inflammatory and autoimmune disorders23–25. Compared to 
their human counterparts, mouse neutrophils are significantly less frequent in the blood (75–90% lymphocytes, 
10–25% neutrophils)42, and also exhibit functional differences, e.g. in terms of the expression of immunological 
Figure 2. Confirmation of selective survival regulatory capacity of IVIG in human but not mouse neutrophils 
by different death assays. Features of cell death assessed in GM-CSF primed or unprimed human (PMNH) 
or C57BL/6 mouse (PMNBL/6) neutrophils following treatment with IVIG by flow cytometry (A–C) or light 
microscopy (D). (A) Annexin V-FITC/PI staining assay. Quantitative analysis is indicated as the percentage 
representative of each quadrant. (B) DNA-fragmentation assay. Quantitative analysis of gated subdiploid 
DNA is indicated. (C) Assessment of mitochondrial potential (Δψm). The mitochondrial uncoupler FCCP 
was used as a positive control. Results of 5- (C) or 15-hour cultures (A,B,D) are shown. (D) Morphological 
characterization. Cells were stained with Giemsa–May–Grünwald (Diff-Quik) (original magnification X1000). 
Continuous arrows indicate condensed nuclei, dashed arrows vacuoles. The lower panel represents the statistical 
analysis of the normal, apoptotic or vacuolated phenotypes. Data are representative for at least 3 independent 
experiments. Bars show mean ± SEM. *p < 0.05, **p < 0.01, one way-ANOVA followed by Dunnet’s post hoc 
test. Δψm = mitochondrial potential.
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effector molecules43. In both species, neutrophil clearance by death is considered an efficient means to control 
this cell type26, 28, 44, which also represents one pharmacodynamic effect of IVIG on human neutrophils9, 29–32. 
We11, 39, 45 and others1, 4 have tested human IVIG in xenogeneic animal models and gained significant mechanistic 
insights. However, in the present work we show that mouse neutrophils are resistant to IVIG-mediated cell death, 
indicating that animal models do not show, or, potentially, even provide misleading information on the important 
effects of IVIG on neutrophils and neutrophil-modulated processes24, 25 that are relevant for the pathogenesis of 
human disease.
We observed that IVIG induced death of human neutrophils in a cytokine-dependent manner, a finding that is 
in line with previous publications29, 30. Similarly, clinical studies reported decreased peripheral neutrophil counts 
after IVIG-treatment in patients suffering from ITP46 or neuroimmunologic disorders47. The augmented sensitiv-
ity of human neutrophils under inflammatory conditions, and thus increased IVIG potency, might be beneficial 
in terms of primarily targeting neutrophils at the site of inflammation. This phenomenon might also explain 
the relative sparing effect on resting neutrophils (yet, transient neutropenia is sometimes observed upon IVIG 
treatment7, 48), dependence of IVIG efficacy on disease stage, and the pharmacodynamics efficacy of specific anti-
bodies at low frequency in IVIG5. Previous reports showed that death-promoting effects of IVIG on human neu-
trophils are F(ab’)2-mediated29, 30, and involve the action of agonistic antibodies to Fas and Siglec-9 receptors29–31, 
whereby the cytokine-dependent effects seem to be mediated by functional anti-Siglec-9 antibodies in IVIG29. 
Further, several studies associated the effects of IVIG on human neutrophils with an enhancement of autophagic 
activities49–51.
Both, quiescent and primed neutrophils are known to express the Fc receptors CD16, CD32 and CD6452. Here, 
we provide a novel insight that Fc-fragments of IVIG have no effect on neutrophil viability, supporting the notion 
that IVIG-mediated neutrophil death relies entirely on specific functional antibodies rather than on unspecific or 
Fc-γ receptor dependent mechanisms. In contrast to the effects on human neutrophils, neither total IVIG nor its 
Figure 3. Human neutrophil susceptibility to death stimuli is specific, Fc-independent, and differs from 
responses of mouse neutrophils. Death of human (PMNH) or mouse C57BL/6 (PMNBL/6) polymorphonuclear 
neutrophils as assessed by flow cytometric ethidium bromide exclusion assay. Results of 24-h cultures of 
quiescent or GM-CSF primed cells are shown following treatment with (A) 20 mg/ml of whole IgG (Privigen#B) 
or equimolar concentrations of Fc-, or F(ab’)2 (Gammavenin)-fragments of pooled IgG, or with (B) stimuli 
known to trigger human neutrophil death including IVIG (Prigiven#A), Fas-ligand, anti-human Fas (clone 
CH11) mAb or anti-Siglec-9 mAb. Bars show mean ± SEM. Data are representative of at least 3 (B), or 4 (A) 
independent experiments. *p < 0.05, **p < 0.01, Student t test. Specific death was calculated in comparison to 
untreated controls as outlined in the Materials and Methods section.
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F(ab’)2- or Fc-fragments affected survival of peripheral blood or bone marrow neutrophils derived from C57BL/6 
or BALB/c mice. Despite evidence of IVIG-binding to self-antigens53, to our knowledge no reports show clinically 
relevant tissue-destruction related to autoreactivity by antibody-dependent cellular cytotoxicity (ADCC) follow-
ing IVIG administration.
Commercial IVIG preparations, including Immunovenin-intact, Hizentra, Sandoglobulin and two dif-
ferent lots of Privigen, all similarly induced cytokine-dependent death of human, but not mouse, neutrophils. 
Absence of IVIG-mediated death was confirmed in different death assays, including flow cytometric assessment 
of Annexin-V/PI staining or ethidium bromide exclusion, DNA fragmentation, mitochondrial potential meas-
urement, and morphological analysis. These data demonstrate that IVIG mediates death of human neutrophils 
by the action of specific antibodies directed to targets that are recognized and functional in human, but not in 
mouse neutrophils.
Treatment with Siglec-9-specific mAb resulted in cytokine-dependent death of human neutrophils, but 
expectedly had no effect on mouse neutrophils on which this receptor is absent. The functional orthologue of 
human Siglec-9 in mice is Siglec-E54, but it remains to be shown if this receptor is capable to activate death path-
ways in mouse neutrophils. Fas is expressed in both species, and mouse neutrophils were highly susceptible to Fas 
ligand-mediated death. In contrast, a human-specific anti-Fas mAb induced human neutrophil death, but failed 
to induce apoptosis in mouse cells. It is likely that the clone differentially recognized antigenic structural determi-
nants on human and mouse Fas, but might also be related to subtle differences in proximal signaling events. These 
data illustrate how specific antibodies to known targets of IVIG, i.e. Fas and Siglec-929–31, are functional on human 
neutrophils, but dysfunctional on mouse neutrophils, due to species-related differences in receptor expression, 
signaling or cellular biology.
To avoid species-related bias of xenogeneic IVIG we additionally tested the susceptibility to polyclonal 
IgG-induced neutrophil cell death in a mouse analogue, i.e. a mouse polyclonal preparation of pooled IgG anti-
bodies (IgGMice), as a substitute for studies in mice. However, IgGMice did not promote death in neutrophils of 
Figure 4. Mouse polyclonal IgG does not induce cell death in mouse neutrophils. Flow cytometric 
characterization of C57BL/6 mouse neutrophil cell death of unprimed or primed cells by mouse polyclonal 
IgG (IgGMice). Representative example of Annexin V-FITC/PI staining assay (A) and statistical summaries (B) 
of Annexin−/PI−-, Annexin+/PI−- and Annexin+/PI+-gated cell populations are indicated for analysis after 
15 h incubation with polyclonal mouse IgG. (C) Death of mouse C57BL/6 mouse (PMNBL/6) or BALB/c mouse 
(PMNBALB/c) neutrophils after IgG stimulation as assessed by ethidium bromide exclusion assay. (D) Binding 
profiles of IgGMice or IVIG to 609 glycan antigens, as assessed by glycan array technology. RFU = relative 
fluorescence units. Bars show mean ± SEM (n = 3). *p < 0.05. One way-ANOVA followed by Dunnets posttest. 
Specific death was calculated in comparison to untreated controls as outlined in the Materials and Methods 
section.
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C57BL/6 nor BALB/c mice. Glycan array technology has previously been used to assess immunoprofiles of IVIG 
preparations5, 55–58, and has recently revealed species-related differences in antigen recognition patterns of sera by 
Stowell et al.41. Using this technology we observed that the immunoprofiles of IgGMice and (human) IVIG differed 
dramatically. Given these species-related differences in specificities, as well as the known differences in antibody 
isotypes and Fc-receptors59, the use of IgGMice in animal models appears inadequate as a substitute for xenogeneic 
IVIG for the study of neutrophil-dependent or –independent immune responses.
In 2004 Mestas and Hughes described differences between mouse and human immunology, and highlighted a 
tendency to ignore differences in experimental models with the associated risk of overlooking aspects of human 
immunology that do not occur, or cannot be modeled, in mice59. Indeed, such differences have led to many con-
troversies in different areas of experimental immunology, including B cell biology60, 61, models of inflammatory 
diseases62, 63, immune thrombocytopenia18, or multiple sclerosis (MS)59, 64. In many cases, protective effects of 
agents observed in animal models had no effects in the clinics, as for IVIG treatment in MS64, or even led to 
disease exacerbation, as observed for IFN-γ in MS65, or to unexpected, even life-threatening, immune reactions 
in humans, as in the case of the first phase 1 trial of TGN1412 (anti-CD28 mAb)66–68. Recent evidence showed 
that high-dose IVIG treatment protects from experimental autoimmune encephalomyelitis [EAE], a widely used 
mouse model for MS, if administered during disease induction, probably by binding to mycobacterial antigens 
in Freund’s complete adjuvant which is required to facilitate active induction39. In contrast, IVIG even exacer-
bated EAE symptoms if applied 7 days after disease induction39. Responses to IVIG in a mouse model of ITP was 
dependent on strain differences19. As pointed out by Mestas and Hughes, it is imperative to understand the poten-
tial limitations of extrapolating data from mice to humans, especially where complex multicomponent processes 
differ59, 64. Inherent challenges working with IVIG are imposed by its pleiotropic pharmacodynamics actions17, 
19 and its xenogeneicity in mice that is associated with gain- or loss-of-function effects7. A better understanding 
of the limitations of current models for IVIG will lead to more caution in interpreting preclinical data obtained 
in mice17, 39, 60–63, and to an improved study design of in vivo studies, e.g. with use of humanized mice that are 
increasingly being used in specific areas of immunology69, 70. However, while humanized mice display an interest-
ing alternative to classical mouse models in many immunological aspects, the granulocyte fraction in such mod-
els is underrepresented and only accounts for about 3% of the leucocytes71, thereby impeding the investigation 
of neutrophil-driven effects. Accordingly, in regards of granulocyte biology, there is a need of refined humanized 
mouse models with adequate granulocyte fractions. Significant differences between mouse and human immunol-
ogy have evolved as a tribute to evolutionary divergence of the species between 65 and 75 million years ago, life 
in different ecological niches, and differences in size and lifespan59. While well-designed animal studies may have 
value in the identification of potential mechanisms, it will remain key to verify such effects in a human system7, 
and to note species-related differences, when they occur59. The findings of our study indicate the need to establish 
experimental systems that take into account the divergent species-related effects of IVIG on neutrophils.
Materials and Methods
Material. The polyclonal IgG preparations used in this study were Privigen, Hizentra, Sandoglobulin (all 
CSL Behring, Bern, Switzerland) and Immunovenin-Intact (BulBio-NCIPB, Sofia, Bulgaria). Vehicle (250 mM 
proline) control for Privigen was used to exclude potential IgG-independent effects (Supplementary Fig. 8). 
Gamma-Venin, a clinical preparation consisting out of F(ab’)2 fragments from pooled human plasma IgG, was 
from Ceneton Pharma, Wien, Austria. Polyclonal pooled mouse serum IgG was from MP Biomedicals (Santa 
Ana, CA, US). Anti-human IgG monoclonal antibody (mAb) (clone HP-6043-Biot), recognizing all IgG subtypes, 
and streptavidin–Alexa 633 as well as goat-anti mouse IgG (Alexa Fluor 633) were purchased from Invitrogen, 
Life Technologies.
To obtain Fc fragments from human IgG, the Streptococcus pyogenes endopeptidase Ide-S (also called Mac-1) 
was used72. Therefore, the cDNA of Ide-S was cloned into the pET28a (GE Healthcare, Little Chalfont, US) expres-
sion vector. The expression of the resulting HIS-tagged protein was induced in BL21 E. coli (NEB) using 0.1 mM 
IPTG for 3 hours at 37 °C and the protein was purified using HISTrap HP columns (GE healthcare Little Chalfont, 
US) according to the manufacturers recommendations using Äkta prime plus (GE healthcare Little Chalfont, 
US). To obtain Fc fragments of IgG, 300 mg IVIG (Privigen) was incubated with 2 mg Ide-S for at least 8 hours. 
Digested IVIG was applied to a HiLoad 26/60 Superdex 75 prep grade column (GE Healthcare Little Chalfont, 
US) and the fractions containing Fc were collected, concentrated (using Amicon Ultra 15 ml centrifugal filter 
units; Millipore), sterile filtered and stored at 4 °C until use11. For quality control, a coomassie stained SDS-PAGE 
under reducing conditions (5 µg/lane loaded) is shown in Supplementary Fig. 7A. In addition, a size-exclusion 
chromatography was performed to verify the integrity of the Fc fragments after IdeS-digestion (Supplementary 
Fig. 7B).
Cell isolation and cell culturing. Human blood was taken from healthy individuals following informed 
and written consent in accordance with the Declaration of Helsinki. All experimental protocols were approved 
by the local institutional and/or licensing committees in Bern and Zürich (Kantonale Ethikkomission; Cantonal 
Animal Care Committee), Switzerland, by the University Health Network Animal Research Committee in 
Toronto, Canada, by the Animal Care Committee at the Institute of Microbiology, Sofia according to the ARRIVE 
(Animal Research: Reporting of In Vivo Experiments), National and European Guidelines and in accordance 
with the National Institutes of Health guidelines for the care and use of experimental animals. All methods were 
carried out in accordance with relevant guidelines and regulations.
Human neutrophils were isolated from peripheral blood of healthy donors by density gradient centrifugation, 
as previously described73. Briefly, granulocytes and erythrocytes were separated from peripheral blood mononu-
clear cells (PBMCs) by density gradient using Pancoll (Pan-Biotech, Aidenbach, Germany). The granulocytes and 
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erythrocytes were treated with erythrocyte lysis solution (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.3), 
resulting in cell populations containing at least 95% neutrophils.
C57BL/6 and BALB/c wild-type mice were maintained under pathogen-free conditions. Mouse bone mar-
row derived neutrophils were isolated from WT mice using magnetic bead based sorting for GR-1high express-
ing neutrophils as previously described40. Analogous, mouse neutrophils were isolated from mouse peripheral 
blood. Cells were cultured at 2 × 106/mL in the presence or absence of cytokines, Abs, or both, for the indicated 
times using complete culture medium for human (RPMI 1640 containing 10% FCS and 200 IU/mL penicil-
lin/100 μg/mL streptomycin; Life Technologies, Basel, Switzerland) or mouse (RPMI 1640/GlutaMax contain-
ing 10% FCS and 200 IU/mL penicillin/100 μg/mL streptomycin, 50 μM 2-mercaptoetanol; Life Technologies, 
Basel, Switzerland) neutrophils. Unless otherwise indicated, cells were stimulated with 20 mg/mL polyclonal IgG 
preparations or the equimolar amount of Fc and F(ab’)2 fragments. Cytokine stimulation with human GM-CSF 
(25 ng/mL; Novartis Pharma GmbH, Nürnberg, Germany) or mouse GM-CSF (1ng/ml, PeproTech, London, 
UK) occurred 20 minutes before the addition of polyclonal IgG. Further details are provided below and in 
Supplementary Material.
Determination of cell death and apoptosis. Cell death was assessed by uptake of 1 μM ethidium bro-
mide (Invitrogen, Lucerne, Switzerland) and subsequent flow cytometric analysis (FACSVerse; Becton Dickinson 
Biosciences) as previously described73. Redistribution of phosphatidylserine (PS) in presence of propidium iodide 
(PI; Sigma-Aldrich, Buchs, Switzerland) and DNA fragmentation were assessed by flow cytometry as previously 
described73. Recombinant His6-tagged annexin V-FITC, Fas-Ligand (FasL, at 100 ng/ml) and FasL cross-linker 
(anti-FLAG at 2 μg/ml) were from Alexis (Enzo) and Sigma, respectively. Anti-Fas/CH11 (MBL international 
corporation distributed by Lab Fore AG, Nunningen, Switzerland) was used at 20 μg/ml. Anti-Siglec-9 (Becton 
Dickinson Bioscience, Allschwil, Switzerland) was used at 35 μg/ml in combination with 20 μg/ml unlabeled 
F(ab’)2 fragments of secondary GaM Ab (Jackson ImmunoResearch Laboratories, Baltimore, US). Specific cell 
death was calculated as previously described73:
= − − × .Specific death (cell death[%] death control[%])/(100 death control[%]) 100
For light microscopic (Zeiss AX10) analysis, 100 cells were evaluated in respect to their morphology as pre-
viously described29.
Mitochondrial Potential. Mitochondrial potential was assessed using TMRE-Mitochondrial membrane 
potential assay kit ab113852 (Abcam, Cambridge, UK) according to the manufactures protocol. Briefly, freshly 
isolated human neutrophils were incubated for 5 h with or without polyclonal IgG. Carbonyl cyanide 4-(trif-
luoromethoxy)phenylhydrazone (FCCP) was added (50 μM) for 10 min at 37 °C as a positive control. To assess 
mitochondrial membrane potential, the cells were stained for 30 min at 37 °C with 100 nM TMRE and assessed by 
flow cytometry (FACSVerse; Becton Dickinson Biosciences).
Glycan array analysis. The glycan microarrays from the CFG (Version 5.1) were prepared from amine func-
tionalized glycan structures covalently coupled in microarrays to N-hydroxysuccinimide–derivatized microscope 
slides as previously described74. In accordance to previous publication5, 55, Privigen as well as polyclonal pooled 
mouse serum IgG were screened at 180 μg/ml. In previous studies, vehicle-dependent effects have been excluded 
at the same concentration5, 55. Data are expressed the mean of relative fluorescence units (RFU).
Complete Freund’s adjuvant (CFA) in vivo priming. In order to prime neutrophils in vivo, six-week-old 
female C57BL/6 mice (Janvier Labs) were injected with complete Freund’s adjuvant (CFA; Difco Laboratories). 
On the day of injection, CFA was diluted in a 1:1 ratio with PBS by vigorously mixing the emulsion for 15 min 
via transfer in between two syringes connected to each other by a Luer-Lock connector. Mice were anesthetized 
by isoflurane inhalation and subsequently injected s.c with 100 µl of the emulsion on both sides of the lateral 
abdomen using a 24 G × 1″ needle. After 24 h of placing the CFA depots, mice were euthanized by CO2 inha-
lation. For analysis of peripheral neutrophils, whole blood was immediately collected into EDTA-microtainer 
tubes (BD Bioscience) via cardiac puncture with a 29 G × 0.5″ micro-fine needle (BD Bioscience). Spleens were 
carefully removed and collected in 15 ml tubes containing cold R10. Spleens were homogenized by passing them 
through a 70um cell strainer. Subsequently, erythrocytes were lysed using 150 mM NH4Cl, 12 mM NaHCO3, 
0.1 mM EDTA (pH = 8.0) in ddH2O. Subsequent neutrophil isolation was performed as previously described40. 
Analogous, neutrophils were isolated from peripheral blood. In vivo priming was verified by flow cytometric 
assessment of CD11b staining. Freshly isolated neutrophils from spleen were therefore stained 30 min at 4 °C 
with FITC-conjugated anti-CD11b (BioLegend). Mean fluorescence ratio (MFI-ratio) was calculated by dividing 
fluorescence intensity of anti-CD11b stained cells by the fluorescence intensity of a FITC-conjugated isotype 
control (BioLegends).
Statistical analysis. Statistical analysis was performed as indicated in the figure legends using GraphPad 
Prism (GraphPad Software Inc., version 6.0c). If mean levels are presented, SEM and number (n) of independent 
experiments are indicated. The p values < 0.05 were considered as statistically significant.
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